How a therapeutic antibody is metabolized in the body is pertinently relevant to its efficacy. Therefore, pharmacokinetics study is an important part of the drug development. PD-1 is probably the most targeted molecule in today’s pharmaceutical industry, thanking to the clinical success of Keytruda® and Opdivo®. Many investigational anti-PD-1 mAbs are being developed. There is a growing need for a standard assay that can be used to facilitate the study of their pharmacokinetics.
It is for research use only.
See Certificate of Analysis for details of reconstitution instruction and specific concentration.
Upon receipt, please store all items at -20℃. After reconstitution, the stock solution should be kept at -80℃.
It is recommended not to freeze thaw more than 3 times.
This product is stable after storage at: Room temperature (RT) for 1 month in lyophilized state; -20℃ for 1 year in lyophilized state; -80℃ for 4 months under sterile conditions after reconstitution.
The enclosed ELISA assay kit for anti-PD-1 h-mAb in human serum is based on an enzyme immunoassay (ELISA) between recombinant PD-1 protein (ECD) and a biotinylated anti-PD-1 monoclonal antibody. The method employs the principle of competitive ELISA, allowing quantification of monoclonal anti-PD-1 antibodies in human serum.
The assay only involves the following steps:
1. Coat the plate with human PD-1;
2. Add the mixture of your sample and biotinylated anti-PD-1 antibody;
3. Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate;
541. Record the OD readings and analyze the serum concentration.